Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 2/20 | 0.48 |
| ▸ | MMP9 | P14780 | 2/20 | 0.48 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | C3AR1 | Q16581 | 3/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | ECE1 | P42892 | 1/20 | 0.38 |
| ▸ | GGH | Q92820 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1086444 | 1.00 | KMT2A (0.49) | KMT2AMMP2MMP9NAALAD2CA2 | |
| SCHEMBL5840489 | 0.82 | MMP2 (0.49) | MMP2MMP9CA2CA1C3AR1 | |
| SCHEMBL6152839 | 0.82 | MMP2 (0.49) | MMP2MMP9CA2CA1C3AR1 | |
| SCHEMBL9725920 | 0.77 | MME (0.49) | MMP9MME | |
| SCHEMBL3448329 | 0.72 | KMT2A (0.64) | KMT2AMMP2MMP9NAALAD2CA2 | |
| SCHEMBL3448327 | 0.72 | KMT2A (0.64) | KMT2AMMP2MMP9NAALAD2CA2 | |
| SCHEMBL6426081 | 0.71 | KMT2A (0.56) | KMT2AMMP2MMP9NAALAD2CA2 | |
| SCHEMBL5283204 | 0.71 | KMT2A (0.56) | KMT2AMMP2MMP9NAALAD2CA2 | |
| SCHEMBL4159914 | 0.71 | KMT2A (0.49) | KMT2AMMP2MMP9NAALAD2CA2 | |
| SCHEMBL28224269 | 0.71 | KMT2A (0.49) | KMT2AMMP2MMP9NAALAD2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1353672-B1 | SYNTHESIS OF 4-AMINO-THALIDOMIDE ENANTIOMERS | CHILDRENS MEDICAL CENTER (US) | 2007-10-03 | — | — | EP | claimed |
| US-9694015-B2 | Methods for the treatment of locally advanced breast cancer | CELGENE CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| EP-3096142-A2 | METHODS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR | Celgene Corporation (US) | 2016-11-23 | — | — | EP | disclosed |
| US-20160319005-A1 | METHODS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR | CELGENE CORPORATION | 2016-11-03 | — | — | US | disclosed |
| US-9365640-B2 | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor | CELGENE CORPORATION (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150224104-A1 | METHODS FOR THE TREATMENT OF LOCALLY ADVANCED BREAST CANCER | CELGENE CORPORATION | 2015-08-13 | — | — | US | disclosed |
| EP-2892537-A1 | METHODS FOR THE TREATMENT OF LOCALLY ADVANCED BREAST CANCER | Celgene Corporation (US) | 2015-07-15 | — | — | EP | disclosed |
| WO-2014039960-A1 | METHODS FOR THE TREATMENT OF LOCALLY ADVANCED BREAST CANCER | CELGENE CORPORATION (US) | 2014-03-13 | — | — | WO | disclosed |
| EP-2702410-A2 | METHODS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR | Celgene Corporation (US) | 2014-03-05 | — | — | EP | disclosed |
| US-20120322073-A1 | METHODS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR | CELGENE CORPORATION | 2012-12-20 | — | — | US | disclosed |
| US-20070105903-A1 | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | CELGENE CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-7153867-B2 | Use of nitrogen substituted thalidomide analogs for the treatment of macular degenerator | CELGENE CORPORATION (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1423115-A4 | SYNTHESIS AND ANTI-TUMOR ACTIVITY OF NITROGEN SUBSTITUTED THALIDOMIDE ANALOGS | CHILDRENS MEDICAL CENTER (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1353672-A4 | SYNTHESIS OF 3-AMINO-THALIDOMIDE AND ITS ENANTIOMERS | CHILDRENS MEDICAL CENTER (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040147558-A1 | Synthesis of 3-amino-thalidomide and its enantiomers | CHILDREN'S MEDICAL CENTER CORPORATION, THE | 2004-07-29 | — | — | US | disclosed |
| EP-1423115-A2 | SYNTHESIS AND ANTI-TUMOR ACTIVITY OF NITROGEN SUBSTITUTED THALIDOMIDE ANALOGS | The Children's Medical Center Corporation (US) | 2004-06-02 | — | — | EP | disclosed |
| EP-1353672-A2 | SYNTHESIS OF 3-AMINO-THALIDOMIDE AND ITS ENANTIOMERS | The Children's Medical Center Corporation (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030139451-A1 | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | CHILDREN'S MEDICAL CENTER CORPORATION, THE | 2003-07-24 | — | — | US | disclosed |
| WO-2003014315-A2 | SYNTHESIS AND ANTI-TUMOR ACTIVITY OF NITROGEN SUBSTITUTED THALIDOMIDE ANALOGS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2003-02-20 | — | — | WO | disclosed |
| WO-2002064083-A2 | SYNTHESIS OF 3-AMINO-THALIDOMIDE AND ITS ENANTIOMERS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160319005-A1 | METHODS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR | CRBN, SERPINA6, TSG101 | KMT2A 4065/4885MMP2 3096/4885MMP9 3899/4885 |
| US-20120322073-A1 | METHODS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR | CRBN, SERPINA6, TSG101 | KMT2A 4065/4885MMP2 3096/4885MMP9 3899/4885 |
| US-20030139451-A1 | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | VEGFA, FLT4, FLT1 | KMT2A 2462/4885MMP2 1927/4885MMP9 3174/4885 |
| US-20150224104-A1 | METHODS FOR THE TREATMENT OF LOCALLY ADVANCED BREAST CANCER | BRCA1, TP53, CCR3 | KMT2A 2923/4885MMP2 344/4885MMP9 196/4885 |
| US-20040147558-A1 | Synthesis of 3-amino-thalidomide and its enantiomers | FLT4, KDR, FLT1 | KMT2A 1136/4885MMP2 4647/4885MMP9 4454/4885 |
| US-20070105903-A1 | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | VEGFA, FLT4, FLT1 | KMT2A 2462/4885MMP2 1927/4885MMP9 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.